Effect of Electroacupuncture on Obesity

Prior treatment

• Patients who are taking medication which cause clinically significant weight gain or loss;

Other illness

• Patients with secondary obesity caused by drugs or neuro-endocrine-metabolic disorders (such as hypothalamic disease and hypopituitarism);
• Patients who have been diagnosed with type I or type II diabetes;
• Patients whose Hamilton 17-item Depression Scale (HAMD-17) score \>18 or have a history of other severe psychiatric disorders;
• Patients with severe ulcer, abscess and skin infection at the local acupuncture area;
• Patients with severe diseases of multiple organs, such as heart, brain, lungs, liver, kidneys, hematopoietic system or other serious diseases;

Other

• Participants who have joined in other clinical trials or studies within the past 1 month;
• Pregnant or lactating women.

• Male or female participants aged 18-65;
• Participant whose BMI is ≥24.0 kg/m2;
• Participants whose HbA1c measurement of 5.7-6.4% both inclusive, or fasting plasma glucose measurement ≥ 6.1 mmol/liter and \<7.0 mmol/liter, or 2-hour plasma glucose measurement post-challenge (oral glucose tolerance test) ≥7.8 mmol/liter and \<11.1 mmol/liter;
• Participants with stable weight within 3 months before the start of the trial, fluctuated within 4 kg;
• Participants who voluntarily agree with the investigation and sign a written informed consent form for the clinical trial.